Overview

Adult RSV vaccination safety requires reading a possible harm alongside protection, not treating a warning as proof of causation or as irrelevant. FDA required a GBS warning for Abrysvo and Arexvy after postmarketing evidence suggested increased risk during the 42 days after vaccination. A Medicare self-controlled case-series study of beneficiaries aged 65 years or older estimated about 9 excess GBS cases per million Abrysvo doses and 7 per million Arexvy doses, subject to observational uncertainty. The estimates are not personal probabilities or product rankings. FDA said causality was unestablished and benefits continued to outweigh risks, while ongoing monitoring keeps the product, population, outcome, and time-window boundaries visible.

Learning outcomes

The GBS warning for Abrysvo and Arexvy signals a possible increased risk during the first 42 days; it does not establish causality.
Among Medicare beneficiaries aged 65 years or older, estimates were about 9 excess cases per million Abrysvo doses and 7 per million Arexvy doses.
FDA says benefits of Abrysvo and Arexvy continue to outweigh risks, while the evidence remains product- and population-specific and under monitoring.

Keywords

GBSSafetyAbrysvoArexvyCausalityMonitoring

How Safety Signals Belong in the Decision

The safety question in adult RSV vaccination is not simply whether a warning sounds alarming. It is how a rare neurological signal should be interpreted alongside protection against hospitalization, what the evidence actually establishes, and which people and products the signal covers. The FDA’s Guillain-Barré syndrome warning for Abrysvo and Arexvy offers a concrete test of that reasoning: acknowledge a possible harm, quantify it on an absolute scale, keep causality uncertain when it is uncertain, and still evaluate the overall balance of benefits and risks.

A warning begins with a signal, not a verdict

Guillain-Barré syndrome, often abbreviated GBS, is a rare disorder in which the immune system damages nerve cells. It can cause muscle weakness and, in some cases, paralysis. Because the outcome is serious even when it is uncommon, a possible increase after vaccination matters to patients, clinicians, and regulators. But the seriousness of an outcome does not answer the separate question of how often vaccination causes it.

FDA required and approved changes to the prescribing information for Pfizer’s Abrysvo and GSK’s Arexvy. The revised Warnings and Precautions section says that the results of a postmarketing observational study suggest an increased risk of GBS during the 42 days after vaccination with each of those vaccines.

The wording is deliberate. “Suggest an increased risk” is a signal that deserves action and continued investigation. It is not the same as saying that every case after vaccination was caused by the vaccine. FDA evaluated data from clinical trials, reports submitted to the Vaccine Adverse Event Reporting System, and the postmarketing study. After considering that totality of evidence, the agency concluded that the overall body of evidence suggested increased risks with Abrysvo and Arexvy, but was insufficient to establish a causal relationship.

This distinction is central to reading any postmarketing safety action. A vaccine can be associated with an event in observed data for several reasons. The event may be caused by the vaccine, partly related to the vaccine, clustered by chance, or made more visible because millions of doses have been given and surveillance has become more attentive. A warning does not settle those possibilities by itself. It records that the signal has crossed a threshold at which prescribers and patients should be informed.

The process can be understood as an evidence sequence:

sequenceDiagram participant Trial as Clinical trial data participant VAERS as VAERS reports participant Study as Medicare postmarketing study participant FDA as FDA evaluation participant PI as Prescribing information participant Monitor as Ongoing monitoring Trial->>FDA: Provide initial safety observations VAERS->>FDA: Add reports after vaccination Study->>FDA: Compare 1–42 day risk window with 43–90 day control window FDA->>FDA: Evaluate the totality, while causality remains uncertain FDA->>PI: Add GBS warning for Abrysvo and Arexvy FDA->>Monitor: Continue safety assessment and updates

A label warning is therefore a communication and monitoring action. It makes the potential harm visible without pretending that the evidence is more conclusive than it is.

Published by DeepMox

FAQ

How many excess GBS cases did the postmarketing study estimate?

It estimated approximately 9 excess hospitalized GBS cases per million Abrysvo doses and 7 per million Arexvy doses during days 1–42 after vaccination, compared with days 43–90, among Medicare beneficiaries aged 65 years or older. These are observational point estimates, not personal probabilities or a product ranking.

Does the FDA warning prove Abrysvo or Arexvy causes GBS?

No. FDA said the postmarketing evidence suggested increased risk but was insufficient to establish a causal relationship. The warning communicates a signal that requires attention and continued investigation.

Which vaccines and age group do the GBS estimates cover?

The warning and excess-risk estimates concern Abrysvo and Arexvy, with estimates from Medicare beneficiaries aged 65 years or older. They should not be silently generalized to mResvia or every adult age group.

Previous12 minAdult RSV Vaccination: Timing and Products

Next14 minAdult RSV Vaccination Decision Framework

Adult RSV Vaccination Safety Signals

How Safety Signals Belong in the Decision

A warning begins with a signal, not a verdict

FAQ